STTR Phase I: Improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries

这一小型企业技术转让(STTR)第一阶段项目的更广泛影响/商业潜力旨在减少因创伤而引起的并发症。目前的创伤治疗是系统性的、非靶向性的，副作用大，疗效低。拟议的项目将开发一种缓释、可生物降解的纳米药物输送系统，用于治疗软组织创伤并发症。这项技术的成功商业化可能会推动持续释放技术的最先进水平，并通过满足提高药物依从性的关键需求以及创伤手术后开出的药物的有效性和安全性，显著提高创伤患者的护理标准。这一小型企业技术转让(STTR)第一阶段项目将通过开发一种缓释、可生物降解的药物输送平台，在受伤组织内输送创伤后药物，从而消除不必要的系统性给药需求，从而满足改善创伤治疗的需要。这种技术有可能改善创伤后损伤患者的外科手术的临床结果，并降低与创伤手术患者的额外手术和康复相关的社会成本。此外，预计这种药物-设备组合将减少手术次数，节省资金，并防止受影响患者的并发症。在第一阶段，该团队建议在体外和体内证明通过纳米技术改变异位骨微环境的可行性，以防止异位骨的发育和进展。这项技术使用了装载Hedgehog途径抑制剂的免疫调节纳米颗粒。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project seeks to reduce complications due to trauma. Current traumatic injury treatments are systemic and untargeted with unwanted side effects and low efficacy. The proposed project will develop a sustained-release, biodegradable, nanoparticle drug delivery system for treatment of soft tissue trauma complications. The successful commercialization of this technology may advance the state of the art in sustained release technologies and dramatically improve the standard of care for trauma patients by addressing critical needs to enhance medication compliance, as well as the efficacy and safety of medications prescribed following trauma surgery. This Small Business Technology Transfer (STTR) Phase I project will address the needs to improve traumatic injury treatments through the development of a sustained-release, biodegradablem drug delivery platform that delivers post traumatic medications within the injured tissue thereby obviating the need for unnecessary systemic drug administration. Such a technology has the potential to improve the clinical outcomes of surgical procedures for patients with post traumatic injuries and reduce societal costs associated with additional surgeries and rehabilitation among trauma surgery patients. In addition, it is anticipated that this drug-device combination will reduce surgery times, save money, and prevent complications among affected patients. During Phase I, the team proposes to demonstrate in vitro and in vivo feasibility towards altering the ectopic bone microenvironment with the aid of nanotechnology that will prevent ectopic bone development and progression. The technology uses immunomodulatory nanoparticles loaded with the Hedgehog pathway inhibitor.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.